KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Deferred Taxes: 2012-2025

Historic Deferred Taxes for Halozyme Therapeutics (HALO) over the last 6 years, with Sep 2025 value amounting to -$27.4 million.

  • Halozyme Therapeutics' Deferred Taxes fell 9267.81% to -$27.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.1 million, marking a year-over-year increase of 91.64%. This contributed to the annual value of -$532,000 for FY2024, which is 98.46% up from last year.
  • Halozyme Therapeutics' Deferred Taxes amounted to -$27.4 million in Q3 2025, which was down 485.59% from $7.1 million recorded in Q2 2025.
  • Over the past 5 years, Halozyme Therapeutics' Deferred Taxes peaked at $142.5 million during Q3 2021, and registered a low of -$27.4 million during Q3 2025.
  • For the 3-year period, Halozyme Therapeutics' Deferred Taxes averaged around -$4.8 million, with its median value being -$3.9 million (2023).
  • Over the last 5 years, Halozyme Therapeutics' Deferred Taxes had its largest YoY gain of 321.38% in 2025, and its largest YoY loss of 9,267.81% in 2025.
  • Halozyme Therapeutics' Deferred Taxes (Quarterly) stood at $13.0 million in 2021, then slumped by 213.30% to -$14.7 million in 2022, then skyrocketed by 35.79% to -$9.4 million in 2023, then skyrocketed by 262.28% to $15.3 million in 2024, then crashed by 9,267.81% to -$27.4 million in 2025.
  • Its last three reported values are -$27.4 million in Q3 2025, $7.1 million for Q2 2025, and $2.9 million during Q1 2025.